id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-010929-d598h08w	Kashiwagi, Hirokazu	Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision	2020-01-02		.txt	text/plain	11814	563	42	Patients who do not achieve the therapeutic target with corticosteroids or require long-term administration of high-dose corticosteroids, or patients unable to tolerate corticosteroids due to complications or adverse drug reactions, are transitioned to second-line treatment. High-dose intravenous immunoglobulin, methylprednisolone pulse therapy, or platelet transfusion should be considered for patients with severe bleeding symptoms, marked thrombocytopenia or who urgently require an increase in their platelet count because of surgery or for some other reason. In patients with underlying diseases (hypertension,diabetes,active infections, chronic infections,impaired immune status,osteoporosis,dys lipidemia,peptic ulcer, etc.) with a high probability of problematic adverse drug reactions associated with corticosteroid treatment, it is recommended that corticosteroids be started while controlling complications. However, the percentage of patients who had a partial response with a platelet count of 30,000-50,000/μL was 57.6% in the rituximab group and 46.7% in the standard treatment group, with a relative risk of 1.26 (95% CI: 0.95-1.67, p = 0.11), indicating that there was no significant difference in the bleeding inhibition effect between the two groups.	./cache/cord-010929-d598h08w.txt	./txt/cord-010929-d598h08w.txt